From Glioblastoma Treatments
Jump to navigationJump to search
|
|
| Line 1: |
Line 1: |
| {{TreatmentInfo
| | |
| |drug_name=Berberine
| |
| |FDA_approval=No
| |
| |used_for=Glioblastoma Multiforme (GBM)
| |
| |OS_without=Not explicitly mentioned; refer to specific studies for detailed metrics.
| |
| |OS_with=Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates.
| |
| |clinical_trial_phase=Pre-clinical (in vitro and in vivo studies)
| |
| |common_side_effects=Not specifically listed for GBM treatment; generally well-tolerated but can include gastrointestinal discomfort at high doses.
| |
| |mechanism_of_action=Berberine exhibits anticancer activity by inhibiting cell proliferation and invasion, suppressing tumor angiogenesis, and inducing cell apoptosis. It has shown potential to sensitize temozolomide-resistant GBM cells, suggesting its utility in overcoming treatment resistance.
| |
| |notes=Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment.
| |
| |category=Nutraceuticals and herbals
| |
| |toxicity_level=3
| |
| }}
| |
Latest revision as of 08:29, 27 March 2024
